Company intelligence / Profile preview

Zedira

Darmstadt, Hesse, Germanyzedira.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Zedira’s lead candidate, ZED1227, is a first-in-class oral tissue transglutaminase inhibitor. It demonstrated proof-of-concept and a placebo-like safety profile in a Phase 2a study for celiac disease. The company has additional small-molecule inhibitors targeting various indications related to dysregulated transglutaminases

Therapeutic areas: PulmonologyGastroenterologyOncologyNephrologyCardiovascular
Modalities: Small moleculePeptidomimetic compoundRecombinant protein (for research reagents)
Industry: Biotech

Drug pipeline

2 assets

ZED1227

1 more asset in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceuticals (collaboration and licensing agreement for celiac disease therapy development)Dr. Falk Pharma

Beyond the preview

Go deeper on Zedira.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zedira.

Explore the full profile